Prof. Dr R I Gregory and his co-workers from Boston Children’s Hospital, MA, USA; Department of Biological Chemistry and Molecular Pharmacology and Department of Pediatrics, Harvard Medical School, Boston, MA, USA; and Harvard Stem Cell Institute, Boston, MA, USA had reported in the prestigious journal Cell (Feb 27, 2014) that “Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer”
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for cancer: MiRNA-181 increases wide-spread miRNA biogenesis via down regulation of its target gene.
Significance: It is known for years that miRNA biogenesis is decreased in a number of cancer cells. This study suggests, for the first time, that MiRNA-181, by suppressing the expression of its target gene, it may increase wide-spread miRNA biogenesis. Thereby, it may inhibit cancer progression. Thus, pharmacological formulations encompassing “MiRNA-181 or its activators” may be used to inhibit cancer progression.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for cancer: MiRNA-181 increases wide-spread miRNA biogenesis via down regulation of its target gene, 14/February/2015, 12.15 am
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation
Undisclosed information: How miR-181 increases wide-spread miRNA biogenesis